Fly News Breaks for May 19, 2017
May 19, 2017 | 08:50 EDT
BMO Capital analyst Alex Arfaei says that "the ASCO abstracts solidify Merck's (MRK) significant leadership in the important 1L-NSCLC market." The analyst says that Incyte's (INCY) Epacadostat appears to be "adding meaningful clinical benefit to Keytruda." He believes that the data "clearly indicates" that Keytruda monotherapy should be the standard of care in about 25% of 1L-NSCLC patients.
News For MRK;INCY From the Last 2 Days
Sep 22, 2017 | 07:21 EDT
Merck's anti-PD-1 therapy, seeking approval for treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have already received two or more lines of chemotherapy, was granted Priority Review with a PDUFA Date of September 22, 2017.